uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience. (Lindholm)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience. (Lindholm)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience. (Lindholm)
Show others and affiliations
2007 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 110, no 6, 2084-2091 p.Article in journal (Refereed) Published
Abstract [en]

Incorporation of apoptosis-inducing agents into current therapeutic regimens is an attractive strategy to improve treatment for drug-resistant leukemia. We tested the potential of arsenic trioxide (ATO) to restore the response to dexamethasone in glucocorticoid (GC)–resistant acute lymphoblastic leukemia (ALL). Low-dose ATO markedly increased in vitro GC sensitivity of ALL cells from T-cell and precursor B-cell ALL patients with poor in vivo response to prednisone. In GC-resistant cell lines, this effect was mediated, at least in part, by inhibition of Akt and affecting downstream Akt targets such as Bad, a proapoptotic Bcl-2 family member, and the X-linked inhibitor of apoptosis protein (XIAP). Combination of ATO and dexamethasone resulted in increased Bad and rapid down-regulation of XIAP, while levels of the antiapoptotic regulator Mcl-1 remained unchanged. Expression of dominant-active Akt, reduction of Bad expression by RNA interference, or overexpression of XIAP abrogated the sensitizing effect of ATO. The inhibitory effect of XIAP overexpression was reduced when the Akt phosphorylation site was mutated (XIAP-S87A). These data suggest that the combination of ATO and glucocorticoids could be advantageous in GC-resistant ALL and reveal additional targets for the evaluation of new antileukemic agents.

Place, publisher, year, edition, pages
2007. Vol. 110, no 6, 2084-2091 p.
Keyword [en]
Antineoplastic Agents/administration & dosage/*pharmacology, Apoptosis/drug effects, Arsenicals/*administration & dosage/pharmacology, Blotting; Western, Caspases, Cell Line; Tumor/drug effects, Cell Survival/drug effects, Dexamethasone/*pharmacology, Drug Resistance; Neoplasm, Drug Synergism, Glucocorticoids/*pharmacology, Humans, Neoplasm; Residual/diagnosis, Oxides/*administration & dosage/pharmacology, Phosphorylation/drug effects, Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/metabolism/pathology, Prednisone/pharmacology, Proto-Oncogene Proteins c-akt/*metabolism, RNA; Small Interfering/pharmacology, Reactive Oxygen Species/metabolism, Remission Induction, Signal Transduction, Sirolimus/pharmacology, Transfection, X-Linked Inhibitor of Apoptosis Protein/metabolism, bcl-Associated Death Protein/metabolism
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-12885DOI: 10.1182/blood-2006-12-060970ISI: 000249671700056PubMedID: 17537996OAI: oai:DiVA.org:uu-12885DiVA: diva2:40655
Available from: 2008-01-18 Created: 2008-01-18 Last updated: 2011-01-25Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=17537996&dopt=Citation

Search in DiVA

By author/editor
Lindholm, Dan
By organisation
Department of Neuroscience
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 135 hits
ReferencesLink to record
Permanent link

Direct link